Ashland Announces Klucel xtend HPC Matrix Former
Klucel xtend HPC is the latest addition to the company’s Klucel product line and further expands their controlled-release portfolio.
Ashland announced the introduction of Klucel xtend hydroxypropyl cellulose (HPC) controlled release matrix former on Oct. 3, 2022. It is designed to deliver process versatility and release profile efficiency.
According to a company press release, Klucel xtend HPC has been shown to match the release profile of widely used Hypromellose controlled-release formulations at half the polymer concentration. Prior to this product launch, Ashland claims that there were limited options for managing the release profile of controlled release formulations, especially high dose.
The reduced polymer concentration offers the possibility of smaller pills or higher dosage, presenting an option for easier tablet swallowability or a reduction in the number of tablets required for frequent medication. According to the release, this feature is intended to improve patient compliance with drug regimens.
Source: Ashland
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
